Results 91 to 100 of about 5,159 (186)

CBD for CLN2 disease [dataset]

open access: yes
This dataset provides supporting data for the manuscript titled "Chronic oral cannabidiol delays or prevents seizures in a mouse model of CLN2 disease" and is deposited to comply with PLOS One data availability requirements.
Jian, Xing
core   +1 more source

The neuronal ceroid lipofuscinosis type 2 – associated variants: An analysis of alterations in the TPP1 gene and genotype–phenotype correlation in Ukraine

open access: yesJIMD Reports
The neuronal ceroid lipofuscinosis type 2 (CLN2) is a heterogeneous group of neurodegenerative lysosomal storage disorders caused by autosomal recessive inheritance of two pathogenic variants in trans in the TPP1 gene.
Nataliia Olkhovych   +11 more
doaj   +1 more source

MoMtg1 Acts as a Novel Transcriptional Repressor of MoSwi6 During Appressorium‐Mediated Penetration in the Rice Blast Fungus

open access: yesAdvanced Science, Volume 12, Issue 43, November 20, 2025.
Appressoria are specialized penetration structures for many plant pathogenic fungi, demanding precise cell cycle control. This study unveils MoMtg1 as a transcriptional repressor of MoSwi6, orchestrating MoCYC1 expression during turgor‐driven cell cycle progression to enable appressorium‐mediated penetration. Moreover, a small‐molecule inhibitor ZS1619
Xingyu Wang   +11 more
wiley   +1 more source

Trial Readiness: Understanding the Natural History of Rare Diseases

open access: yesJournal of Inherited Metabolic Disease, Volume 48, Issue 6, November 2025.
ABSTRACT Inherited metabolic diseases (IMD) represent the largest and still growing group of treatable genetic disorders and are increasingly amenable to targeted interventions that achieve varying degrees of prognostic improvement. Innovative therapies are on the horizon and offer promising opportunities for disease‐changing treatment for a variety of
Thomas Opladen   +6 more
wiley   +1 more source

SIT4 protein phosphatase is required for the normal accumulation of SWI4, CLN1, CLN2, and HCS26 RNAs during late G1 [PDF]

open access: yes, 1992
In Saccharomyces cerevisiae, the RNA levels of the G1 cyclins CLN1, CLN2, and HCS26 increase dramatically during the late G1 phase of the cell cycle.
Zhong, T.   +7 more
core   +1 more source

Proteins at the CLN2 promoter.

open access: yes, 2013
(A) Map of the CLN2 promoter, showing the location of the up, sbf, and dwn probes in the BBP1-CLN2 intergenic region. The sbf probe overlaps the consensus SBF binding sites. The dyn probe is in the middle of the DYN1 open reading frame, several kilobases
Herman Wijnen (61991)   +4 more
core   +1 more source

Overexpression of CLN1, CLN2, or ERG13 increases resistance to adriamycin in Saccharomyces cerevisiae

open access: yesThe Journal of Toxicological Sciences, 2011
To elucidate the mechanisms underlying adriamycin resistance, adriamycin resistance-related genes were explored using the budding yeast Saccharomyces cerevisiae as a useful eukaryotic model. The CLN1 and CLN2 genes, encoding G1 cyclin, and the ERG13 gene, encoding 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase, were identified.
Takahashi, Tsutomu   +5 more
openaire   +3 more sources

Positive feedback in CLN2 activation and the coherence of entry into Start.

open access: yes, 2016
A and B. Joint distributions of the times from birth to the activation of the genes for RAD27 (Tbir,RAD27) and CLN2 (Tbir,CLN2) are plotted for WT and cln1Δcln2Δ cells from single-cycle simulations for an extant population of 500 mother (blue) and 500 ...
Jean Peccoud (142023)   +3 more
core   +1 more source

Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses

open access: yesAnnals of Clinical and Translational Neurology, 2018
Objective Neuronal Ceroid Lipofuscinoses (NCL) are fatal inherited neurodegenerative diseases with established neuronal cell death and increased ceramide levels in brain, hence, a need for disease‐modifying drug candidates, with potential to enhance ...
Joelle Makoukji   +7 more
doaj   +1 more source

FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.

open access: yesPLoS ONE, 2020
PurposeTo provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat lysosomal storage disorders (LSDs).MethodsAssessment of the drug pipeline through analysis of the FDA database ...
Sven F Garbade   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy